drugset / Trial / NCT02611882

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882

Phase 2 Completed 225 enrolled Thomas Hope
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy, patients with biochemical recurrence and patients with castrate resistant prostate cancer.

Timeline

Start
2015-12-18
Primary completion
2016-10-24
Completion
2016-10-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 10 ug Intravenous
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 25 ug Intravenous
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 111 mbq Intravenous
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 259 mbq Intravenous

Indications